CA2260777A1 - Pentafluorobenzenesulfonamides and analogs - Google Patents

Pentafluorobenzenesulfonamides and analogs

Info

Publication number
CA2260777A1
CA2260777A1 CA002260777A CA2260777A CA2260777A1 CA 2260777 A1 CA2260777 A1 CA 2260777A1 CA 002260777 A CA002260777 A CA 002260777A CA 2260777 A CA2260777 A CA 2260777A CA 2260777 A1 CA2260777 A1 CA 2260777A1
Authority
CA
Canada
Prior art keywords
analogs
agents
compositions
pentafluorobenzenesulfonamides
pentafluorophenylsulfonamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002260777A
Other languages
French (fr)
Other versions
CA2260777C (en
Inventor
John Flygare
Julio Medina
Bei Shan
David Clark
Terry Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Tularik, Inc.
John Flygare
Julio Medina
Bei Shan
David Clark
Terry Rosen
Arrow Acquisition, Llc
Amgen Sf, Llc
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tularik, Inc., John Flygare, Julio Medina, Bei Shan, David Clark, Terry Rosen, Arrow Acquisition, Llc, Amgen Sf, Llc, Amgen Inc. filed Critical Tularik, Inc.
Publication of CA2260777A1 publication Critical patent/CA2260777A1/en
Application granted granted Critical
Publication of CA2260777C publication Critical patent/CA2260777C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C07C313/06—Sulfinamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/46—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms
    • C07C323/49—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms to sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention provides methods and compositions relating to novel pentafluorophenylsulfonamide derivatives and analogs and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly cancer, vascular restenosis, microbial infections, and psoriasis, or as lead compounds for the development of such agents. The compositions include compounds of general formula (I).
CA002260777A 1996-07-19 1997-07-18 Pentafluorobenzenesulfonamides and analogs Expired - Fee Related CA2260777C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2219896P 1996-07-19 1996-07-19
US60/022,198 1996-07-19
PCT/US1997/012720 WO1998005315A1 (en) 1996-07-19 1997-07-18 Pentafluorobenzenesulfonamides and analogs

Publications (2)

Publication Number Publication Date
CA2260777A1 true CA2260777A1 (en) 1998-02-12
CA2260777C CA2260777C (en) 2006-06-13

Family

ID=21808333

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002260777A Expired - Fee Related CA2260777C (en) 1996-07-19 1997-07-18 Pentafluorobenzenesulfonamides and analogs

Country Status (15)

Country Link
US (2) US6482860B1 (en)
EP (1) EP0939627B1 (en)
JP (1) JP3421350B2 (en)
CN (1) CN1147294C (en)
AT (1) ATE249214T1 (en)
AU (1) AU710173B2 (en)
BR (1) BR9710737A (en)
CA (1) CA2260777C (en)
DE (1) DE69724811T2 (en)
DK (1) DK0939627T3 (en)
ES (1) ES2201313T3 (en)
HK (1) HK1021699A1 (en)
IL (2) IL127965A0 (en)
PT (1) PT939627E (en)
WO (1) WO1998005315A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0896533B1 (en) * 1996-02-22 2003-09-10 Tularik, Inc. Pentafluorobenzenesulfonamides and analogs
JP3421350B2 (en) * 1996-07-19 2003-06-30 テュラリク インコーポレイテッド Pentafluorobenzenesulfonamide and analogs
JP2002518506A (en) 1998-06-25 2002-06-25 テュラリク インコーポレイテッド Aryl sulfone anilide phosphate
US6153585A (en) 1998-07-20 2000-11-28 Tularik Inc. Arylsulfonanilide derivatives
SK284757B6 (en) * 1998-09-23 2005-11-03 Tularik Inc. Arylsulfonanilide ureas, pharmaceutical composition containing them and use thereof
EP1285911A3 (en) * 1998-09-23 2003-03-26 Tularik Inc. Arylsulfonanilide ureas
AU731777B2 (en) * 1998-11-30 2001-04-05 Nihon Nohyaku Co., Ltd. Aniline derivative and process for producing the same
WO2000035865A2 (en) * 1998-12-17 2000-06-22 Tularik Inc. Tubulin-binding agents
JP2001026506A (en) * 1999-04-28 2001-01-30 Takeda Chem Ind Ltd Sulfonamide derivative
US6521658B1 (en) 1999-05-28 2003-02-18 Abbott Laboratories Cell proliferation inhibitors
CO5170498A1 (en) * 1999-05-28 2002-06-27 Abbott Lab BIARIL SULFONAMIDS ARE USEFUL AS CELL PROLIFERATION INHIBITORS
WO2001008693A2 (en) * 1999-07-29 2001-02-08 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamide and platin compound
AU1806800A (en) * 1999-08-17 2001-03-13 Tularik Inc. Arylsulfonanilide derivatives
US6306615B1 (en) 1999-08-19 2001-10-23 Tularik Inc. Detection method for monitoring β tubulin isotype specific modification
US6432427B1 (en) 2000-06-30 2002-08-13 Unilever Hope & Personal Care Usa, Division Of Conopco, Inc. Cosmetic compositions containing substituted sulfonamide derivatives
AU9619301A (en) * 2000-10-20 2002-04-29 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
US20050250854A1 (en) * 2000-11-03 2005-11-10 Amgen Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
US6822001B2 (en) 2000-11-03 2004-11-23 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
FR2836914B1 (en) * 2002-03-11 2008-03-14 Aventis Pharma Sa SUBSTITUTED INDAZOLES, COMPOSITIONS CONTAINING SAME, METHOD OF MANUFACTURE AND USE
US6946466B2 (en) 2003-04-10 2005-09-20 Schering Ag Aromatic sulfonamides as peroxynitrite-rearrangement catalysts
EA200501607A1 (en) * 2003-04-14 2006-06-30 ДЗЕ ИНСТИТЬЮТС ФОР ФАРМАСЬЮТИКАЛ ДИСКАВЕРИ, ЭлЭлСи REPLACED PHYLALICANE ACIDS
WO2005007621A2 (en) * 2003-05-30 2005-01-27 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
AU2005302475A1 (en) * 2004-10-28 2006-05-11 The Institutes For Pharmaceutical Discovery, Llc Substituted phenylalkanoic acids
DE102006016258A1 (en) * 2005-05-14 2007-02-15 Universität Stuttgart New non, partially or perfluorinated aromatic, monomeric, oligomeric, polymeric sulfone- and/or phosphonic acids, produced by nucleophilic aromatic substitution with sulfur and/or phosphorous nucleophile, useful e.g. in membrane procedure
GB0526445D0 (en) * 2005-12-23 2006-02-08 Novartis Ag Organic compounds
KR100932093B1 (en) 2006-09-27 2009-12-16 주식회사종근당 Benzophenone Derivatives Useful as Inhibitors of Microtubule Formation
JP2013532688A (en) * 2010-07-26 2013-08-19 ブリストル−マイヤーズ スクイブ カンパニー Sulfonamide compounds useful as CYP17 inhibitors
CN104447536B (en) * 2014-10-25 2017-04-12 大连理工大学 Preparation method of N-2-quinolyl aryl sulfonamide compounds
US20200277268A1 (en) * 2017-09-21 2020-09-03 Dalriada Therapeutics Inc. Pentafluorophenyl sulfonamide compounds, compositions and uses thereof
US11555012B2 (en) * 2018-11-09 2023-01-17 Nimbus Artemis, Inc. ACLY inhibitors and uses thereof
US20220169598A1 (en) * 2019-03-27 2022-06-02 2681603 Ontario Inc. Halogenated phenylsulfonamide hydroxamic acid compounds, compositions and uses thereof as selective hdac6 inhibitors
EP4017843A4 (en) * 2019-07-17 2023-07-26 2692372 Ontario, Inc. Benzenesulfonamide derivatives and uses thereof
KR20230147036A (en) * 2020-11-20 2023-10-20 2692372 온타리오 인크. Benzenesulfonamide derivatives and uses thereof
WO2022106897A2 (en) * 2020-11-20 2022-05-27 2692372 Ontario, Inc. Methods and composition for kras modifications

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1955207A (en) 1931-09-16 1934-04-17 Ig Farbenindustrie Ag Mothproofing agent
US2402623A (en) 1943-06-24 1946-06-25 Rohm & Haas Nu-nitroaryl haloarylsulphonamides
CH362688A (en) * 1957-09-10 1962-06-30 Geigy Ag J R Process for the preparation of new arylsulfonarylamides
GB1242057A (en) 1968-07-04 1971-08-11 Ici Ltd Derivatives of 4-hydroxytetrafluoropyridine and the use thereof as plant growth regulators
NL174644C (en) 1970-04-13 1984-07-16 Minnesota Mining & Mfg METHOD FOR PREPARING A HERBICIDE COMPOUND; ALSO METHOD FOR PREPARING A PREPARATION WITH HERBICIDE ACTION.
DE3000377A1 (en) * 1980-01-07 1981-07-09 Boehringer Mannheim Gmbh, 6800 Mannheim NEW SULPHONAMIDES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
DE3623184A1 (en) 1986-07-10 1988-01-14 Kali Chemie Ag METHOD FOR PRODUCING N-FLUORSULFONAMIDES
DE3632329A1 (en) * 1986-09-24 1988-03-31 Bayer Ag SUBSTITUTED PHENYLSULPHONAMID
US4883914A (en) 1987-08-17 1989-11-28 American Cyanamid Company Benzenesulfonyl carboxamide compounds useful as herbicidal agents
DE3804990A1 (en) 1988-02-18 1989-08-31 Basf Ag HERBICIDALLY EFFECTIVE, HETEROCYCLICALLY SUBSTITUTED SULFONAMIDES
FR2645537B1 (en) 1989-04-05 1994-03-04 Fabre Medicament Pierre NOVEL SULFONAMIDES DERIVED FROM BENZOCYCLIC OR BENZOHETEROCYCLIC ACIDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR2665440B1 (en) 1990-07-31 1994-02-04 Lipha NOVEL SUBSTITUTED CYCLOALKYLSULFONAMIDES, METHODS OF PREPARATION AND MEDICAMENTS CONTAINING THEM.
US5189211A (en) 1990-08-01 1993-02-23 Taisho Pharmaceutical Co., Ltd. Sulfonamide derivatives
ATE167473T1 (en) * 1990-08-20 1998-07-15 Eisai Co Ltd SULFONAMIDE DERIVATIVES
CH681529A5 (en) 1990-08-21 1993-04-15 Alusuisse Lonza Services Ag
DE19581653T1 (en) * 1994-05-25 1997-07-17 Dow Chemical Co Sulfonamides, usable as lubricants in magnetic recording media
AU6112896A (en) * 1995-06-07 1996-12-30 Sugen, Inc. Tyrphostin-like compounds for the treatment of cell prolifer ative disorders or cell differentiation disorders
EP0896533B1 (en) 1996-02-22 2003-09-10 Tularik, Inc. Pentafluorobenzenesulfonamides and analogs
JP3421350B2 (en) * 1996-07-19 2003-06-30 テュラリク インコーポレイテッド Pentafluorobenzenesulfonamide and analogs
US5773236A (en) * 1997-04-25 1998-06-30 Molecule Probes, Inc. Assay for glutathiane transferase using polyhaloaryl-substituted reporter molecules
US6284923B1 (en) * 1997-08-22 2001-09-04 Tularik Inc Substituted benzene compounds as antiproliferative and cholesterol lowering action
AU1208999A (en) 1997-11-10 1999-05-31 Array Biopharma, Inc. Compounds which inhibit tryptase activity
US6153585A (en) * 1998-07-20 2000-11-28 Tularik Inc. Arylsulfonanilide derivatives
US6521658B1 (en) * 1999-05-28 2003-02-18 Abbott Laboratories Cell proliferation inhibitors
WO2001008693A2 (en) * 1999-07-29 2001-02-08 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamide and platin compound
US6822001B2 (en) * 2000-11-03 2004-11-23 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents

Also Published As

Publication number Publication date
JP2000515545A (en) 2000-11-21
EP0939627B1 (en) 2003-09-10
ATE249214T1 (en) 2003-09-15
EP0939627A4 (en) 2000-10-04
ES2201313T3 (en) 2004-03-16
DK0939627T3 (en) 2003-10-13
DE69724811T2 (en) 2004-04-08
DE69724811D1 (en) 2003-10-16
IL127965A0 (en) 1999-11-30
US20030162817A1 (en) 2003-08-28
CN1147294C (en) 2004-04-28
US6482860B1 (en) 2002-11-19
PT939627E (en) 2004-02-27
EP0939627A1 (en) 1999-09-08
CA2260777C (en) 2006-06-13
US6962929B2 (en) 2005-11-08
AU3887797A (en) 1998-02-25
HK1021699A1 (en) 2000-06-30
IL127965A (en) 2006-08-20
AU710173B2 (en) 1999-09-16
CN1225009A (en) 1999-08-04
WO1998005315A1 (en) 1998-02-12
JP3421350B2 (en) 2003-06-30
BR9710737A (en) 2000-01-11

Similar Documents

Publication Publication Date Title
CA2260777A1 (en) Pentafluorobenzenesulfonamides and analogs
CA2244785A1 (en) Pentafluorobenzenesulfonamides and analogs
CA2343204A1 (en) Arylsulfonanilide ureas
WO1999010320A8 (en) Substituted benzene compounds as antiproliferative and cholesterol lowering agents
MX9702382A (en) New pyrimidone derivatives with antifungal activity.
BG103417A (en) Condensed pyrimidine bicyclic derivatives
MY128063A (en) Aromatic heterocyclic compound as antiinflammatory agents
CA2361998A1 (en) Aromatic heterocyclic compounds as anti-inflammatory agents
CA2258548A1 (en) Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
AU1617901A (en) Urea derivatives as anti-inflammatory agents
ATE353641T1 (en) BENZAMIDE AS POTASSIUM CHANNEL INHIBITORS
GEP20033081B (en) Pharmaceutical Agents for Treatment of Parkinson's Disease, ADFD and Microadenomas
DE69911017D1 (en) Arylsulfonanilid-phosphate
HK1050203A1 (en) Novel fusidic acid derivatives.
SE9902596D0 (en) Pharmaceutically active compounds
EP1285911A3 (en) Arylsulfonanilide ureas
IT1261994B (en) Guanidine derivatives for therapeutic use

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed